Promedior
Lexington
About Promedior
Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and greatly reduce the risk of systemic side effects inherent in current therapeutic approaches. Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma and COPD; and acute and chronic nephropathy.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $63.0M
- Funding stage: M&A
- Last round: Series Unknown (Jan 2019)
- Website: promedior.com
- Phone: 781-538-4200
Industries & Categories
Biopharma, Biotechnology, Health Care, Therapeutics
Canonical: https://fsome.com/organization/promedior-2736272 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.